[Involuntary movements as a complication of treatment of extrapyramidal disorders with L-dopa].
The frequency of dyskinesias connected with L-DOPA treatment of certain extrapyramidal system diseases was studied. Among 111 studied patients with Parkinson's disease drug-induced dyskinesias were observed in 56 cases (that is 50% of the treated patients) while in the group of other extrapyramidal system diseases (torsion dystonia, Hallervorden-Spatz disease, Huntington's chorea with increased muscular tonus) they were observed in only 8 cases (of 73 treated ones - about 11%). Two groups of patients with Parkinson's disease were isolated - differing in the susceptibility to dyskinesia development: those susceptible to dyskinesia which developed nearly immediately after starting treatment, and those non-susceptible, in whom dyskinesia appeared only after years of treatment. The pathomechanism of drug-induced dyskinesia development in these groups is discussed.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002648:Child; D004409:Dyskinesia, Drug-Induced / Q000453:epidemiology*; D004422:Dystonia Musculorum Deformans / Q000188:drug therapy; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D006211:Pantothenate Kinase-Associated Neurodegeneration / Q000188:drug therapy; D012737:Sex Factors
D007980:Levodopa
Ruchy mimowolne jako powikłanie l-dopa terapii chorób układu pozapiramidowego.